Home › Modalities › Protein

Protein (101 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ABSI Absci DermatologyGI/Hepatology+1 6 Phase 1 $1.31B 6
ACIU AC Immune Neurology Rare 5 Phase 3 $210M 11
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 3 Phase 2 $536M 7
ABOS Acumen Pharmaceuticals Neurology 4 Phase 2 $16.6M 4
ADAG Adagene Oncology 10 Phase 2 $99.4M 10
ADCT ADC Therapeutics Oncology 5 Approved $172M 5
ADMA Adma Biologics ImmunologyInfectious Disease Rare 4 Approved $3.02B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 3 Approved $111M 10
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 9 Approved $1.36B 9
ANIX Anixa Biosciences Oncology 2 Phase 1 $92.8M 3
ANNX Annexon HematologyNeurology+2 Rare 5 Phase 3 $662M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 9 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 8 Phase 1 $1.6M 8
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.36B 8
AVBP ArriVent BioPharma Oncology 6 Phase 3 $553M 7
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
BCAX Bicara Therapeutics Oncology 4 Phase 2 $637M 4
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.93B 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $30.7M 8
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
CLDX Celldex Therapeutics DermatologyImmunology+1 6 Phase 3 $2.20B 6
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 4 Phase 2 $13.2M 4
CLYM Climb Bio HematologyImmunology+1 Rare 7 Phase 2 $574M 8
CHRS Coherus Oncology Oncology 5 Approved $74.0M 5
CMPX Compass Therapeutics Oncology 15 Phase 2 $109M 15
CGEN Compugen Oncology 7 Phase 3 $191M 7
CNTB Connect Biopharma Respiratory 4 Phase 2 $37.3M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
COYA Coya Therapeutics Neurology Rare 4 Phase 2 $70.8M 6
CBIO Crescent Biopharma Oncology 10 Phase 2 $507M 10
CUE Cue Biopharma ImmunologyOncology 6 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 9 NDA Submitted $602M 10
CYDY CytoDyn NeurologyOncology 3 Phase 2 $367M 3
CTMX CytomX Therapeutics Oncology 7 Phase 1 $423M 7
DBVT DBV Technologies Immunology 2 NDA Submitted $3.14B 2
IRON Disc Medicine GI/HepatologyHematology+2 Rare 6 Phase 3 $3.49B 9
DYN Dyne Therapeutics MetabolicNeurology Rare 1 NDA Submitted $3.00B 10
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 3 Phase 2 $167M 3
ERAS Erasca Oncology 1 Phase 1 $4.87B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 2 Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 2 Phase 2 $290M 6
EXEL Exelixis CardiovascularOncology 6 Approved $16.7B 23
FBRX Forte Biosciences DermatologyGI/Hepatology 3 Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+4 Rare 5 Approved $61.4M 16
HROW Harrow Ophthalmology Rare 2 Approved $1.11B 15
IDYA IDEAYA Biosciences Oncology 3 NDA Submitted $2.65B 15
IMTX Immatics Oncology 6 Phase 3 $958M 8
IBRX ImmunityBio Infectious DiseaseOncology 7 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 12 Approved $1.44B 12
IMNM Immunome Oncology Rare 7 NDA Submitted $2.03B 9
IMVT Immunovant ImmunologyNeurology Rare 4 Phase 3 $6.87B 4
INAB IN8bio ImmunologyOncology 1 Phase 1 $8.9M 4
INBX Inhibrx Biosciences Oncology 6 NDA Submitted $1.10B 6
INSM Insmed CardiovascularImmunology+3 Rare 3 Approved $26.7B 15
IVVD Invivyd Infectious Disease 5 Approved $152M 5
JBIO Jade Biosciences ImmunologyRenal Rare 4 Phase 2 $1.07B 4
JANX Janux Therapeutics Oncology 4 Phase 1 $655M 4
KAPA Kairos Pharma Oncology 4 Phase 2 $1.9M 12
KROS Keros Therapeutics NeurologyOncology Rare 4 Phase 3 $222M 5
KOD Kodiak Sciences Ophthalmology 8 Phase 3 $6.33B 8
LRMR Larimar Therapeutics Neurology Rare 1 NDA Submitted $313M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $236M 12
MDNAF Medicenna Therapeutics Oncology 10 Phase 2 $14.8M 10
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 4 NDA Submitted $957M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 11 Phase 3 $1.23B 11
NBP NovaBridge Biosciences OncologyOphthalmology 7 Phase 2 $95.4M 7
NRXP NRX Pharmaceuticals Neurology Rare 3 Approved $109M 11
OCGN Ocugen Infectious DiseaseOphthalmology Rare 3 Phase 3 $257M 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $418M 5
OMER Omeros HematologyNeurology+2 Rare 4 Approved $1.04B 6
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
ORKA Oruka Therapeutics DermatologyImmunology Rare 7 Phase 2 $6.53B 7
OTLK Outlook Therapeutics Ophthalmology 3 Approved $87.9M 3
PMN ProMIS Neurosciences Neurology Rare 6 Phase 1 $28.9M 9
QTTB Q32 Bio Dermatology 3 Phase 2 $258M 3
SABS SAB Biotherapeutics Metabolic 1 Phase 2 $266M 1
SPRB Spruce Biosciences Metabolic Rare 2 Preclinical $116M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare 10 Phase 2 $8.91B 10
SMMT Summit Therapeutics Oncology 6 NDA Submitted $8.53B 6
STRO Sutro Biopharma Oncology 3 Phase 1 $148M 3
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $822M 7
TECX Tectonic Therapeutic Cardiovascular Rare 4 Phase 2 $401M 4
TLX Telix Pharmaceuticals Oncology 11 Approved $3.01B 25
TGTX Tg Therapeutics Neurology Rare 5 Approved $9.48B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 5 Phase 2 $83.2M 5
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.91B 7
HURA TuHURA Biosciences Oncology 1 Phase 3 $92.1M 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 5 Approved $1.70B 10
UPB Upstream Bio Respiratory 3 Phase 2 $115M 3
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
PCVX Vaxcyte Infectious Disease 7 Phase 3 $9.40B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 6 Approved $1.89B 6
VIR Vir Biotechnology Infectious DiseaseOncology Rare 6 Phase 3 $1.58B 6
VRDN Viridian Therapeutics ImmunologyOphthalmology 7 Approved $3.41B 7
VOR Vor Biopharma ImmunologyNeurology Rare 2 Phase 3 $1.12B 2
VYGR Voyager Therapeutics MetabolicNeurology Rare 1 Phase 1 $94.6M 9
XNCR Xencor ImmunologyNeurology+1 Rare 28 Approved $2.59B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 7 NDA Submitted $1.88B 11
ZURA Zura Bio DermatologyImmunology Rare 4 Phase 2 $99.7M 4
ZYME Zymeworks OncologyRespiratory 11 Approved $1.78B 12